Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verubecestat in Mild to Moderate Alzheimer's Disease (EPOCH)
NCT01739348Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of verubecestat in Alzheimer's disease (AD), sponsored by Merck & Co.. Started Nov 2012; status: terminated.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01739348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01739348.